Amarin Earnings Call Signals Leaner, Global Growth

Amarin Corporation Plc ((AMRN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Amarin’s latest earnings call struck a cautiously optimistic tone as management balanced solid operational progress with clear near‑term headwinds. Executives highlighted growing revenues, sharply lower operating costs, improving losses and a strengthening cash position, while acknowledging pressure from higher manufacturing costs, U.S. generics and variability tied to its new partnership-driven model.

Revenue Growth and Top-Line Performance

Total net revenue in Q1 2026 climbed to $45.1 million from $42.0 million a year earlier, marking a 7.4% increase despite ongoing U.S. pressure. Management noted that domestic revenue was broadly flat versus Q1 2025, but benefited from an IPE market that expanded about 3% year over year, underscoring resilient demand for the drug class.

U.S. Market Share and Branded Demand

Amarin continued to gain share in the U.S. IPE market, lifting its position to 48% at March 31, 2026 from 42% a year earlier. VASCEPA branded prescriptions rose 17% year over year in the quarter, showing that the franchise still commands strong physician and patient loyalty even as generics intensify pricing and reimbursement pressure.

Recordati Partnership Accelerates European Growth

In Europe, the Recordati partnership began to show meaningful traction, with Q1 2026 product revenue of $4.9 million more than doubling sequentially from $2.3 million in Q4 2025. The jump was driven largely by $3.0 million of supply shipments as Recordati has now launched VAZKEPA in 10 countries, supported by intellectual property protection across 59 markets through 2039.

Global Expansion Beyond Europe

Rest-of-world operations are starting to contribute, with Q1 2026 revenue from partners in China, Australia, Canada and the Middle East reaching $2.8 million versus no revenue a year ago. Amarin is also preparing launches in South Korea and Singapore for early 2027, while regulatory reviews advance in Thailand and the Philippines and filings move forward in Vietnam and Malaysia.

Expense Discipline and Restructuring Progress

The company’s cost-cutting program is gaining traction, as total operating expenses fell 31% year over year to $29.1 million in Q1 2026. Excluding $3.3 million of restructuring charges, expenses were $25.8 million, down 38% from last year, with SG&A dropping 42% and falling to 47% of net sales compared with a burdensome 87% in the prior-year quarter.

Improving Profitability and Cash Generation

Profitability metrics improved, with operating loss narrowing to $11.3 million from $16.8 million in Q1 2025 and to $8.0 million on an ex‑restructuring basis. Importantly for investors, Amarin delivered its second straight quarter of positive operating cash flow at $6.4 million, ending Q1 with $308 million in cash and investments, no debt and working capital of $450 million.

Clinical Backing and Guideline Tailwinds

Management emphasized a favorable clinical and guideline backdrop as a key competitive moat for VASCEPA. Updated 2026 ACC/AHA lipid guidelines highlight icosapent ethyl as the only primary triglyceride-lowering therapy proven to reduce cardiovascular events on top of statins, supported by more than 500 peer‑reviewed papers and over 30 million prescriptions written by roughly 250,000 clinicians.

Higher COGS and Margin Pressure

Against these positives, cost of goods sold rose sharply, up $10.5 million or 62% year over year in Q1, weighing on margins. Management attributed the jump to increased product volumes tied to regained PBM exclusivity in the U.S. and larger supply shipments to partners, and warned that elevated COGS and margin volatility should persist until at least the third quarter of 2026.

European Revenue Under New Model

European revenue of $4.9 million in Q1 2026 was down modestly from $5.4 million a year earlier when Amarin used a direct in‑market sales model. However, executives stressed that revenue is now generated at significantly lower cost under the partnered approach and is showing strong sequential momentum, suggesting better profitability even on slightly lower top-line figures.

Revenue Variability in Partnered Markets

The shift to a partnership-based international strategy introduces additional quarter-to-quarter swings in reported revenue. Launch timing, in‑market uptake, the cadence of bulk supply shipments and milestone structures all contribute to lumpiness, making near-term forecasting more difficult even as the model is designed to improve capital efficiency over time.

Persistent U.S. Generic Competition

Management reiterated that the U.S. business remains exposed to generic erosion, which could pressure volumes and pricing beyond 2026. While Amarin has secured key payer exclusives through the end of 2026, supporting net selling price stability in the near term, investors were reminded that shifts in payor dynamics could accelerate longer-term domestic revenue declines.

Restructuring Charges Near Completion

Restructuring efforts continued to carry a cost in Q1, with charges totaling $3.3 million versus $4.1 million in Q4 2025 and $39.6 million cumulatively. The company expects only a nominal additional charge in Q2 2026, indicating that the heavy lifting on restructuring is nearly complete and that the full run-rate benefits should soon be reflected in results.

Uncertain Timing of Partner Milestones

Although Amarin highlighted potential upside from milestones embedded in partner contracts such as Recordati, management declined to quantify the timing or size of those payments for 2026. This leaves an additional layer of uncertainty around possible revenue boosts from milestones, even as underlying partner launches continue to ramp.

Guidance and Outlook

Looking ahead, Amarin reaffirmed its target of achieving about $70 million in annualized operating expense savings by June 30, 2026 and expects to be cash‑flow positive for the full year. The company plans to maintain key U.S. payer exclusives through 2026, sees COGS remaining elevated until late 2026 due to higher volumes and partner shipments, and views restructuring as largely complete, positioning the business for leaner, more globally leveraged growth.

Amarin’s earnings call painted the picture of a company transitioning from a costly standalone model to a leaner, partnership-led platform with improving cash dynamics. While higher manufacturing costs, generic competition and revenue lumpiness remain concerns, the strengthening balance sheet, expanding global footprint and supportive clinical guidelines suggest a more durable long-term story for investors willing to tolerate near-term volatility.